Lavender Bina Cendikia Tbk. (BMBL)
IDX IDX Primary Summary
Lavender Bina Cendikia Tbk. (BMBL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Lavender Bina Cendikia Tbk. ever had a stock split?
Lavender Bina Cendikia Tbk. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Mr. Joel Bradley Latham CEO | IDX Exchange | ID1000182306 ISIN |
| Australia Country | 9 Employees | - Last Dividend | - Last Split | 2 Mar 2022 IPO Date |
Overview
Incannex Healthcare Inc. is an ambitious clinical-stage biopharmaceutical company based in Sydney, Australia, with a focus on the research, development, manufacture, sale, and distribution of psychoactive medicines and therapies. The company targets a wide spectrum of chronic diseases, leveraging the potential of psychedelic compounds and cannabinoid derivatives. Incannex Healthcare Inc.'s distinctive approach involves combining rigorous scientific research with strategic development efforts to produce novel therapeutic options for patients with unmet medical needs, particularly in areas where traditional treatments have fallen short.
Products and Services
- IHL-42X
- PSX-001
- IHL-675A
An innovative oral fixed-dose combination therapy of dronabinol and acetazolamide, IHL-42X represents a significant breakthrough in the treatment of obstructive sleep apnea. Having completed a pivotal Phase 2/3 clinical trial, the drug is poised to offer a novel treatment option for patients suffering from this common and potentially serious sleep disorder.
PSX-001 is at the forefront of Incannex Healthcare Inc.'s ventures into the therapeutic application of psychedelics, with the drug undergoing Phase 2b clinical development. This oral synthetic psilocybin treatment is aimed at patients with generalized anxiety disorder, signaling the company's commitment to addressing complex mental health issues through the exploration of psychedelics.
As a testament to Incannex Healthcare Inc.'s innovative spirit, IHL-675A merges the therapeutic potentials of synthetic cannabidiol and hydroxychloroquine sulphate into a single oral fixed-dose combination drug. Currently in Phase 2 clinical trials, IHL-675A targets a range of inflammatory and autoimmune conditions, including rheumatoid arthritis, lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease (COPD), asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. This broad-spectrum approach underscores the company's dedication to leveraging cannabinoid science in addressing a wide array of chronic conditions.
